- Acquired by Edwards Lifesciences for $497M, Sep 2025
- Raised $10M Series B led by GEOC, Feb 2018
- Raised $5M Series A led by RAD BioMed, Jan 2015
About
Vectorious Medical Technologies has developed the V-LAP, a miniature, wireless, and battery-free microcomputer that is implanted in the heart's left atrium. This device monitors left atrial pressure (LAP), which is a key early indicator of worsening heart failure. The V-LAP system provides real-time data to enable physician-guided, patient self-management of chronic heart failure, aiming to improve patient outcomes by reducing hospitalizations and enhancing quality of life. The company's technology includes a proprietary ASIC Chip and MEMS, and a home-based processing and communication system that transmits data to a cloud-based system for medical teams to access and analyze. The V-LAP system received FDA breakthrough device designation in 2020.
Funding history · 4 rounds · $19.5M total
Headcount over time
Q&A
- What is Vectorious Medical Technologies' primary product?
- Vectorious Medical Technologies developed the V-LAP, an in-heart microcomputer that monitors the heart's left atrium pressure to enable optimal treatment for heart disease patients.
- When was Vectorious Medical Technologies acquired, and by whom?
- Vectorious Medical Technologies was acquired by Edwards Lifesciences in September 2025 for $497 million.
- What was the total amount of funding raised by Vectorious Medical Technologies before its acquisition?
- Vectorious Medical Technologies raised a total of $35 million in funding.
- When did Vectorious Medical Technologies receive FDA breakthrough device designation for its V-LAP system?
- Vectorious Medical Technologies received FDA breakthrough device designation for its V-LAP system in November 2020.
- What was the outcome of the VECTOR-HF I study for Vectorious Medical Technologies' V-LAP sensor?
- In May 2022, Vectorious Medical Technologies announced that the VECTOR-HF I study confirmed the safety and accuracy of its V-LAP in-heart sensor for left atrial pressure management of heart failure.
- When did Vectorious Medical Technologies begin the VECTOR-HF II study?
- Vectorious Medical Technologies began the VECTOR-HF II study of its implantable in-heart sensor in February 2022.
- Who were the lead investors in Vectorious Medical Technologies' B Round in March 2018?
- The lead investors in Vectorious Medical Technologies' B Round in March 2018 were Broadview Ventures and GEOC.
- How many employees does Vectorious Medical Technologies currently have?
- Vectorious Medical Technologies has 51–200 employees.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | vectoriousmedtech.com |
|---|---|
| linkedin.com/company/5395385 | |
| YouTube | youtube.com/channel/UCDAp3W3D-YAd-dYi7Q4wFog |
Identifiers & details
| Legal name | VECTORIOUS MEDICAL TECHNOLOGIES LTD |
|---|---|
| Founded | 2011-10 |
| Employees (exact) | 120 |
| Status reason | Acquired by Edwards Lifesciences on Sep, 2025 |
Acquisitions & public offerings
Acquired by Edwards Lifesciences 2025-09 $497.0M
Radar intelligence
Patents
| EPO | 10 |
|---|
Web history (Wayback)
| Domain | vectoriousmedtech.com |
|---|
Certificate / subdomain footprint
| Subdomains | 8 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514680974 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2011-10-25 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2025 |
| Active charges / liens | 0 |
| Registry events | 6 — people (2), charge (2), other (1), shares_capital (1) |
| Registered address | ולנברג ראול 24 תל אביב - יפו |
Recent registry events
| Date | Event |
|---|---|
| 2025-09-18 | עדכון דירקטורים-הסרת דירקטור |
| 2025-09-18 | עדכון דירקטורים-הוספת דירקטור |
| 2026-02-17 | רישום שעבוד |
| 2025-09-09 | שינוי בתקנון |
| 2025-09-08 | העברת מניות |
| 2025-11-03 | סילוק שעבוד |